达希斐®上市加速 复锐医疗科技长效A型肉毒毒素产品通过中检院质量标准检验

复星
Jan 07

内容来源:复锐医疗科技2026年1月5日,复星医药控股子公司复锐医疗科技宣布旗下长效A型肉毒毒素产品达希斐®(英文商标DAXXIFY)已正式通过中国食品药品检定研究院(简称“中检院”)的质量标准检验,标志着达希斐®在质量、安全性与有效性方面均符合国家药品监管体系的严格要求,顺利完成上市前的最终关键环节。达希斐®是全球首款且唯一一款长效肽制剂神经调节剂,其药物活性成分为A型肉毒杆菌毒素(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10